Clinical trial
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
NCT00090519 · Chromaderm, Inc., Industry · Completed
Key facts
| NCT number | NCT00090519 |
|---|---|
| Title | Reduction in the Occurrence of Center-Involved Diabetic Macular Edema |
| Official title | Reduction in the Occurrence of Center-Involved Diabetic Macular Edema |
| Lead sponsor | Chromaderm, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Retinopathy |
| Intervention type | Drug |
| Interventions | ruboxistaurin, placebo |
| Enrollment | 731 |
| Start date | Feb 1, 2004 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Aug 31, 2004 |
| Last update posted | Oct 6, 2016 |
| Countries | Australia, Brazil, Canada, Denmark, France, Germany, India, Italy, Mexico, Netherlands, Poland, Portugal and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: